257 related articles for article (PubMed ID: 32100452)
21. Concurrent Selective Lymph Node Radiotherapy and S-1 Plus Cisplatin for Esophageal Squamous Cell Carcinoma: A Phase II Study.
Wang X; Liu X; Li D; Wang X; Huang W; Li B
Ann Surg Oncol; 2019 Jun; 26(6):1886-1892. PubMed ID: 30805810
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic analysis of definitive radiotherapy for early esophageal carcinoma(T1-2N0M0): a multi-center retrospective study of Jing-Jin-ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group].
Lu N; Wang X; Li C; Wang L; Chen JQ; Zhang WC; Wang XM; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Xiao ZF; Zhu SC; Han C; Qiao XY; Pang QS; Wang P; Zhao YD; Sun XC; Zhang KX; Li L; Li GF; Liu ML; Wang YD
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):139-144. PubMed ID: 32135649
[No Abstract] [Full Text] [Related]
23. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
[TBL] [Abstract][Full Text] [Related]
25. Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial.
Zhao Z; Wen Y; Liao D; Miao J; Gui Y; Cai H; Chen Y; Wei M; Jia Q; Tian H; Sun M; Zhang Y; Feng G; Du X
Oncologist; 2020 Dec; 25(12):e1900-e1908. PubMed ID: 32864805
[TBL] [Abstract][Full Text] [Related]
26. Intensity-modulated radiotherapy with more than 60 Gy improved the survival of inoperable patients with locally advanced esophageal squamous cell carcinoma: A population-based real-world study.
Zhang W; Xie Q; Zhu B; Wang X; He L; Zhang Y
Medicine (Baltimore); 2022 Apr; 101(16):e29166. PubMed ID: 35482986
[TBL] [Abstract][Full Text] [Related]
27. Caution against simultaneous integrated boost radiotherapy for upper thoracic esophageal squamous cell carcinoma: results from a single-arm phase II trial.
Zhou Y; Chu L; Lu S; Chu X; Ni J; Li Y; Guo T; Yang X; Zhu Z
Esophagus; 2023 Oct; 20(4):713-721. PubMed ID: 37149827
[TBL] [Abstract][Full Text] [Related]
28. Elective lymph node irradiation late course accelerated hyper-fractionated radiotherapy plus concurrent cisplatin-based chemotherapy for esophageal squamous cell carcinoma: a phase II study.
Wang D; Yang J; Zhu J; Li B; Zhai L; Sun M; Gong H; Zhou T; Wei Y; Huang W; Wang Z; Li H; Zhang Z
Radiat Oncol; 2013 May; 8():108. PubMed ID: 23638721
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of concurrent selective lymph node late-course accelerated hyperfractionated radiotherapy and S-1 plus cisplatin for locally advanced oesophageal squamous cell carcinoma.
Li M; Fu C; Zhang W; Huang W; Wang Z; Zhou T; Lin H; Li B
Br J Radiol; 2016; 89(1060):20150476. PubMed ID: 26891913
[TBL] [Abstract][Full Text] [Related]
30. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of S-1-Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang X; Han W; Zhang W; Wang X; Ge X; Lin Y; Zhou H; Hu M; Wang W; Liu K; Lu J; Qie S; Zhang J; Deng W; Wang L; Han C; Li M; Zhang K; Li L; Wang Q; Shi H; Yu Z; Zhao Y; Sun X; Shi Y; Pang Q; Zhou Z; Liang J; Chen D; Feng Q; Bi N; Zhang T; Deng L; Wang W; Liu W; Wang J; Zhai Y; Wang J; Chen W; Chen J; Xiao Z;
JAMA Netw Open; 2023 May; 6(5):e2312625. PubMed ID: 37195667
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.
Li H; Fang Y; Gu D; Du M; Zhang Z; Sun L; Zhou G; Ye J
Radiat Oncol; 2022 Jun; 17(1):105. PubMed ID: 35681233
[TBL] [Abstract][Full Text] [Related]
33. A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer.
Li C; Ni W; Wang X; Zhou Z; Deng W; Chang X; Chen D; Feng Q; Liang J; Wang X; Deng L; Wang W; Bi N; Zhang T; Xiao Z
Radiat Oncol; 2019 Mar; 14(1):48. PubMed ID: 30876442
[TBL] [Abstract][Full Text] [Related]
34. Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.
Zhu H; Rivin Del Campo E; Ye J; Simone CB; Zhu Z; Zhao W; Amini A; Zhou J; Wu C; Tang H; Fan M; Li L; Lin Q; Xia Y; Li Y; Li J; Mo M; Jia H; Lu S; Wang J; Nie Y; Chen J; Wu S; Hamaji M; Haque W; Jeong BK; Shridhar R; Zhang Z; Chen Y; Zhao K
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1396-1406. PubMed ID: 33677048
[TBL] [Abstract][Full Text] [Related]
35. A Phase II Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin for Inoperable Esophageal Squamous Cell Carcinoma.
Tang HR; Ma HF; An SM; Badakhshi H; Deng JY; Zhang JH; Chen Y; Zhang Z; Guo XM; Jiang GL; Zhao KL
Am J Clin Oncol; 2016 Aug; 39(4):350-4. PubMed ID: 24732811
[TBL] [Abstract][Full Text] [Related]
36. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
37. Randomised phase III trial of concurrent chemoradiotherapy with extended nodal irradiation and erlotinib in patients with inoperable oesophageal squamous cell cancer.
Wu SX; Wang LH; Luo HL; Xie CY; Zhang XB; Hu W; Zheng AP; Li DJ; Zhang HY; Xie CH; Lian XL; Du DX; Chen M; Bian XH; Tan BX; Jiang H; Zhang HB; Wang JH; Jing Z; Xia B; Zhang N; Zhang P; Li WF; Zhao FJ; Tian ZF; Liu H; Huang KW; Hu J; Xie RF; Du L; Li G
Eur J Cancer; 2018 Apr; 93():99-107. PubMed ID: 29494818
[TBL] [Abstract][Full Text] [Related]
38. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial.
Welsh JW; Seyedin SN; Allen PK; Hofstetter WL; Ajani JA; Chang JY; Gomez DR; Amini A; Swisher SG; Blum MA; Younes AI; Nguyen QN; Minsky BD; Erasmus JJ; Lee JH; Bhutani M; Komaki RU
J Thorac Oncol; 2017 Feb; 12(2):375-382. PubMed ID: 27794500
[TBL] [Abstract][Full Text] [Related]
39. Phase II Trial of Intensity-Modulated Radiotherapy Concurrent With Chemotherapy for Postoperative Node-Positive Esophageal Squamous Cell Carcinoma.
Tao H; Zhou Y; Yao C; Gu D; Chen W; Lu J
Oncol Res; 2017 Sep; 25(8):1357-1362. PubMed ID: 28315293
[TBL] [Abstract][Full Text] [Related]
40. Results of chemoradiotherapy for stage I esophageal cancer in medically inoperable patients compared with results in operable patients.
Jingu K; Matsushita H; Takeda K; Narazaki K; Ariga H; Umezawa R; Sugawara T; Miyata G; Onodera K; Nemoto K; Yamada S
Dis Esophagus; 2013 Jul; 26(5):522-7. PubMed ID: 22925398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
